LY3410738,Venetoclax,Azacitidine
Eli Lilly,Abbvie,Roche
['myeloid', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'valent ,(-prevalent)']
first-in-human phase i study of covalent inhibitor of idh mutations in advanced myeloid cancers shows favorable safety profile (ct026), says dr. courtney dinardo. study has moved treatment into frontline setting in combo therapy. read the abstract #aacr23 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789